
AMNEAL PHARMACEUTICALS INC
AMRXNASDAQTrading Snapshot
- Day Range
- $17.03 β $17.25
- 52-Week Range
- $8.21 β $19.26
- Volume
- $2.24B
- Avg Volume
- $2.37B
- Shares Outstanding
- 319.3M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.02B
- Last Q Revenue
- $796M
- P/E Ratio
- 46.8
- P/S Ratio
- 1.9x
- EPS (TTM)
- $0.37
- Dividend Yield
- β
Why Investors Own AMRX
- βHigh-growth profile β revenue up +5.5% YoY with expanding US Equity exposure.
- βHealthy economics β 51% gross margin and 13% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AMNEAL PHARMACEUTICALS INC
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
AMNEAL PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift AMRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
AMNEAL PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.